Clinical Trial Detail

NCT ID NCT03547973
Title Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Immunomedics, Inc.
Indications

transitional cell carcinoma

Therapies

Sacituzumab govitecan-hziy

Age Groups: senior adult

No variant requirements are available.